The BRANDL TALOS deal team consisted of partner Roman Rericha, attorney Stephan Strass and associate Céline Dobnikar.
Pioneering work by Allcyte has delivered the first clinically validated platform that uses an A.I.-based screening technique to match patients with effective cancer treatments. Therefore, it is possible to select the most promising drug candidates for clinical development to maximize clinical study success rates and patient beneﬁt.
Exscientia, is a U.K. AI-driven pharmatech company that earned accolades as the world’s first company to progress AI-designed small molecules into the clinical setting. The Allcyte transaction comes shortly after Exscientia announced it had received $225 million in Series D venture capital funding from investors that include, among others, SoftBank’s Vision Fund 2, funds managed by BlackRock and Mubadala Investment Co.
By joining Exscientia, Allcyte’s platform will be significantly expanded and extended into early discovery.
Exscientia was advised by Cooley LLP and Kunz Wallentin. SMP (Frederik Gärtner) acted as advisor to the investors.